Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6508
    +0.0008 (+0.12%)
     

  • OIL

    82.95
    +0.14 (+0.17%)
     

  • GOLD

    2,326.90
    -11.50 (-0.49%)
     

  • Bitcoin AUD

    98,691.13
    -4,352.65 (-4.22%)
     

  • CMC Crypto 200

    1,390.19
    -33.91 (-2.38%)
     

  • AUD/EUR

    0.6074
    +0.0004 (+0.06%)
     

  • AUD/NZD

    1.0949
    +0.0007 (+0.06%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,295.93
    +94.66 (+0.55%)
     

  • NIKKEI 225

    37,677.59
    -782.49 (-2.03%)
     

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

Vaccitech (UK) Limited
·2-min read
Vaccitech (UK) Limited
Vaccitech (UK) Limited

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022. The conference will be held both in person in Miami and virtually.

A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location.

About Vaccitech plc
Vaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment of chronic infectious diseases, cancer, autoimmunity and diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections, as well as a few prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

ADVERTISEMENT

Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc. (U.S.)
Email: klarch@burnsmc.com / rflamm@burnsmc.com

Georgy Egorov, Vaccitech
Email: georgy.egorov@vaccitech.co.uk